Putting Evidence Into Practice: Prevention of Infection

Laura J. Zitella

Christopher R. Friese

Joanna (Jody) Hauser

Barbara Holmes Gobel

Myra Woolery

Colleen O'Leary

LCDR Felicia A. Andrews

CJON 2007, 10(6), 739-750. DOI: 10.1188/06.CJON.739-750

Jump to a section

    References

    Agency for Healthcare Research and Quality. (2005). National Guideline Clearinghouse. Retrieved July 1, 2005, from http://www.guidelines.gov
    Bohlius, J., Reiser, M., Schwarzer, G., & Engert, A. (2004). Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma [Cochrane review]. In Cochrane Library, Issue 3. Oxford, UK: Update Software.
    Bow, E.J., Laverdiere, M., Lussier, N., Rotstein, C., Cheang, M.S., & Ioannou, S. (2002). Antifungal prophylaxis for severely neutropenic chemotherapy recipients: A meta analysis of randomizedcontrolled clinical trials. Cancer, 94, 3230-3246.
    Boyce, J.M., & Pittet, D. (2002). Guideline for hand hygiene in health-care settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infection Control and Hospital Epidemiology, 23(12, Suppl.), S3-S40.
    Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M.S., Martinelli, G., et al. (2005). Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. New England Journal of Medicine, 353, 977-987.
    Cascinu, S., Fedeli, A., Fedeli, S.L., & Catalano, G. (1994). Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. European Journal of Cancer, Part B, Oral Oncology, 30B(4), 234-236.
    Centers for Disease Control and Prevention. (2006). Infection control in healthcare settings. Retrieved January 26, 2006, from http://www.cdc.gov/ncidod/dhqp/index.html
    Clarkson, J.E., Worthington, H.V., & Eden, O.B. (2003). Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews, 3, CD000978.
    Cornely, O.A., Ullmann, A.J., & Karthaus, M. (2003). Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood, 101, 3365-3372.
    Cruciani, M., Rampazzo, R., Malena, M., Lazzarini, L., Todeschini, G., Messori, A., et al. (1996). Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: A meta-analysis. Clinical Infectious Diseases, 23, 795-805.
    Cullen, M., Steven, N., Billingham, L., Gaunt, C., Hastings, M., Simmonds, P., et al. (2005). Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. New England Journal of Medicine, 353, 988-998.
    Dale, D.C. (2002). Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs, 62(1), 1-15.
    Elting, L.S., Cooksley, C., Chambers, M., Cantor, S.B., Manzullo, E., & Rubenstein, E.B. (2003). The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer, 98, 1531-1539.
    Engels, E.A., Lau, J., & Barza, M. (1998). Efficacy of quinolone prophylaxis in neutropenic cancer patients: A meta-analysis. Journal of Clinical Oncology, 16, 1179-1187.
    Gafter-Gvili, A., Fraser, A., Paul, M., & Leibovici, L. (2005). Metaanalysis: Antibiotic prophylaxis reduces mortality in neutropenic patients. Annals of Internal Medicine, 142(12, Pt. 1), 979-995.
    Given, B.A., & Sherwood, P.R. (2005). Nursing-sensitive patient outcomes—A white paper. Oncology Nursing Forum, 32, 773-784.
    Glasmacher, A., Prentice, A., Gorschluter, M., Engelhart, S., Hahn, C., Djulbegovic, B., et al. (2003). Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: Evidence from a meta-analysis of 3,597 patients. Journal of Clinical Oncology, 21, 4615-4626.
    Gotzsche, P.C., & Johansen, H.K. (2004). Routine versus selective antifungal administration for control of fungal infections in patients with cancer [Cochrane review]. In Cochrane Library, Issue 3. Oxford, UK: Update Software.
    Hadorn, D.C., Baker, D., Hodges, J.S., & Hicks, N. (1996). Rating the quality of evidence for clinical practice guidelines. Journal of Clinical Epidemiology, 49, 749-754.
    Hughes, W.T., Armstrong, D., Bodey, G.P., Bow, E.J., Brown, A.E., Calandra, T., et al. (2002). 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clinical Infectious Diseases, 34, 730-751.
    Infectious Diseases Society of America. (2005). Infectious Diseases Society of America. Retrieved January 26, 2006, from http://www.idsociety.org
    Johansen, H.K., & Gotzsche, P.C. (2004a). Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia [Cochrane review]. In Cochrane Library, Issue 3. Oxford, UK: Update Software.
    Johansen, H.K., & Gotzsche, P.C. (2004b). Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients [Cochrane review]. In Cochrane Library, Issue 3. Oxford, UK: Update Software.
    Jones, G. (Ed.). (2002). Clinical evidence [concise] (Volume 8). London: BMJ Publishing Group.
    Kanda, Y., Yamamoto, R., Chizuka, A., Hamaki, T., Suguro, M., Arai, C., et al. (2000). Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A metaanalysis of 16 randomized, controlled trials. Cancer, 89, 1611-1625.
    Lalami, Y., Paesmans, M., Aoun, M., Munoz-Bermeo, R., Reuss, K., Cherifi, S., et al. (2004). A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia. Supportive Care in Cancer, 12, 725-730.
    Larson, E., & Nirenberg, A. (2004). Evidence-based nursing practice to prevent infection in hospitalized neutropenic patients with cancer. Oncology Nursing Forum, 31, 717-725.
    Lyman, G.H., Kuderer, N., Agboola, O., & Balducci, L. (2003). Evidence-based use of colony-stimulating factors in elderly cancer patients. Cancer Control, 10, 487-499.
    Lyman, G.H., Kuderer, N.M., & Djulbegovic, B. (2002). Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: A meta-analysis. American Journal of Medicine, 112, 406-411.
    Mahood, D.J., Dose, A.M., Loprinzi, C.L., Veeder, M.H., Athmann, L.M., Therneau, T.M., et al. (1991). Inhibition of fluorouracilinduced stomatitis by oral cryotherapy. Journal of Clinical Oncology, 9, 449-452.
    Mank, A., & van der Lelie, H. (2003). Is there still an indication for nursing patients with prolonged neutropenia in protective isolation? An evidence-based nursing and medical study of 4 years experience for nursing patients with neutropenia without isolation. European Journal of Oncology Nursing, 7, 17-23.
    Mitchell, S.A., & Friese, C.R. (n.d.). Weight of evidence. Retrieved October 19, 2006, from http://www.ons.org/outcomes/tables/sleep/woe.shtml
    Moody, K., Charlson, M.E., & Finlay, J. (2002). The neutropenic diet: What's the evidence? Journal of Pediatric Hematology/Oncology, 24, 717-721.
    National Comprehensive Cancer Network. (2005a). National Comprehensive Cancer Network clinical practice guidelines in oncology: Fever and neutropenia—v. 1.2005. Retrieved February 20, 2006, from http://www.nccn.org/professionals/physician_gls/PDF/fever.pdf
    National Comprehensive Cancer Network. (2005b). National Comprehensive Cancer Network clinical practice guidelines in oncology: Myeloid growth factors—v. 2.2005. Retrieved February 20, 2006, from http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf
    National Library of Medicine. (2005). Fact sheet: Journal selection for MEDLINE. Retrieved January 23, 2006, from http://www.nlm.nih.gov/pubs/factsheets/jsel.html
    Nauseef, W.M., & Maki, D.G. (1981). A study of the value of simple protective isolation in patients with granulocytopenia. New England Journal of Medicine, 304, 448-453.
    Ring, A., Marx, G., Steer, C., & Harper, P. (2002). Influenza vaccination and chemotherapy: A shot in the dark? Supportive Care in Cancer, 10, 462-465.
    Ropka, M.E., & Spencer-Cisek, P. (2001). PRISM: Priority symptom management project phase I: Assessment. Oncology Nursing Forum, 28, 1585-1594.
    Rubenstein, E.B., Peterson, D.E., Schubert, M., Keefe, D., Mc-Guire, D., Epstein, J., et al. (2004). Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer, 100(9, Suppl.), 2026-2046.
    Sehulster, L., & Chinn, R.Y. (2003). Guidelines for environmental infection control in health-care facilities: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). Morbidity and Mortality Weekly Report, Recommendations and Reports, 52(RR-10), 1-44.
    Shelton, B.K. (2003). Evidence-based care for the neutropenic patient with leukemia. Seminars in Oncology Nursing, 19, 133-141.
    Smith, C.M., & Kagan, S.H. (2005). Prevention of systemic mycoses by reducing exposure to fungal pathogens in hospitalized and ambulatory neutropenic patients. Oncology Nursing Forum, 32, 565-579.
    Smith, L.H., & Besser, S.G. (2000). Dietary restrictions for patients with neutropenia: A survey of institutional practices. Oncology Nursing Forum, 27, 515-520.
    Somerville, E.T. (1986). Special diets for neutropenic patients: Do they make a difference? Seminars in Oncology Nursing, 2, 55-58.
    Sung, L., Nathan, P.C., Lange, B., Beyene, J., & Buchanan, G.R. (2004). Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: A meta-analysis of randomized controlled trials. Journal of Clinical Oncology, 22, 3350-3356.
    Tablan, O.C., Anderson, L.J., Besser, R., Bridges, C., & Hajjeh, R. (2004). Guidelines for preventing health-care associated pneumonia, 2003: Recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. Morbidity and Mortality Weekly Report, Recommendations and Reports, 53(RR-3), 1-36.
    U.S. Preventive Services Task Force. (2005). The guide to clinical preventive services 2005: Recommendations of the U.S. Preventive Services Task Force. Retrieved January 26, 2006, from http://www.preventiveservices.ahrq.gov
    van de Wetering, M.D., de Witte, M.A., Kremer, L.C., Offringa, M., Scholten, R.J., & Caron, H.N. (2005). Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: A systematic review of randomised controlled trials. European Journal of Cancer, 41, 1372-1382.
    Viscoli, C. (2002). Management of infection in cancer patients: Studies of the EORTC International Antimicrobial Therapy Group (IATG). European Journal of Cancer, 38(Suppl. 4), 82-87.
    Wilson, B.J. (2002). Dietary recommendations for neutropenic patients. Seminars in Oncology Nursing, 18, 44-49.
    Worthington, H.V., & Clarkson, J.E. (2002). Prevention of oral mucositis and oral candidiasis for patients with cancer treated with chemotherapy: Cochrane systematic review. Journal of Dental Education, 66, 903-911.
    Worthington, H.V., Eden, O.B., & Clarkson, J.E. (2004). Interventions for preventing oral candidiasis for patients with cancer receiving treatment [Cochrane review]. In Cochrane Library, Issue 4. Oxford, UK: Update Software.